Products for Research Use Only

ABR-238901

CAT: 0804-HY-141537-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-141537-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4) . ABR-238901 has the potential for myocardial infarction (MI) research[1][2][3].
CAS Number
1638200-22-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/abr-238901.html
Purity
98.92
Solubility
DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=S(NC1=C(O)C(Cl)=CN=C1)(C2=CN=C(C(Br)=C2)OC)=O
Molecular Formula
C11H9BrClN3O4S
Molecular Weight
394.63
Precautions
H302, H315, H319, H335
References & Citations
[1]Kim De Veirman, et al. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res. 2017 Oct;5 (10) :839-846.|[2]Goran Marinković, et al. S100A9 Links Inflammation and Repair in Myocardial Infarction. Circ Res. 2020 Aug 14;127 (5) :664-676.|[3]A. Schiopu, et al. Short-term blockade of the S100A8/A9 alarmin in the immediate post-myocardial infarction period inhibits acute myocardial inflammation and preserves myocardial repair. European Heart Journal, Volume 38, Issue suppl_1, August 2017, ehx504.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported